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Mónica García-Alloza1,2, Pedro Nunez-Abades2,4 and Carmen Castro 1,2
Hippocampal neurogenesis has widely been linked to memory and learning performance. New neurons generated from neural
stem cells (NSC) within the dentate gyrus of the hippocampus (DG) integrate in hippocampal circuitry participating in memory
tasks. Several neurological and neuropsychiatric disorders show cognitive impairment together with a reduction in DG
neurogenesis. Growth factors secreted within the DG promote neurogenesis. Protein kinases of the protein kinase C (PKC) family
facilitate the release of several of these growth factors, highlighting the role of PKC isozymes as key target molecules for the
development of drugs that induce hippocampal neurogenesis. PKC activating diterpenes have been shown to facilitate NSC
proliferation in neurogenic niches when injected intracerebroventricularly. We show in here that long-term administration of
diterpene ER272 promotes neurogenesis in the subventricular zone and in the DG of mice, affecting neuroblasts differentiation and
neuronal maturation. A concomitant improvement in learning and spatial memory tasks performance can be observed. Insights
into the mechanism of action reveal that this compound facilitates classical PKCα activation and promotes transforming growth
factor alpha (TGFα) and, to a lesser extent, neuregulin release. Our results highlight the role of this molecule in the development of
pharmacological drugs to treat neurological and neuropsychiatric disorders associated with memory loss and a deficient
neurogenesis.
Neuropsychopharmacology (2020) 0:1–13; https://doi.org/10.1038/s41386-020-00934-y
INTRODUCTION
The generation of neurons from neural stem cells (NSC) is a
complex process that occurs in mammals in brain regions referred
to as neurogenic niches; mainly the dentate gyrus of the
hippocampus (DG) and the subventricular zone (SVZ). NSC -or
radial glial like cells in the DG- generate proliferative intermediate
progenitors [1] in both niches, which have the capacity to
generate slow proliferating neuronal progenitors (neuroblasts)
and to a lesser extent glial progenitors, which differentiate into
astrocytes or oligodendrocytes [2, 3]. Neuroblasts differentiate into
mature neurons. Whereas granule cell neurons generated within
the DG integrate into hippocampal circuits, SVZ neuroblasts
migrate toward the olfactory bulb [4, 5] producing olfactory
interneurons. DG neurogenesis has been linked to learning and
memory [6, 7], and a number of different neurological and
neuropsychiatric pathologies, such as depression, and response to
stress [8, 9]. Alterations in the neurogenic rate and a reduction in
the number of granule cells have been associated with depression
and suicidal behavior [10, 11] whereas antidepressants promote
hippocampal neurogenesis in rodents [12]. Neurogenesis is
regulated by growth factors released within the niches such as
neuregulin or transforming growth factor alpha (TGFα), which
activate ErbB receptors within the DG and SVZ, promoting
neurogenesis [13–15]. Interestingly, behavioral alterations have
been found in individuals with disrupted neuregulin signaling [13]
and cognitive improvement has been observed in mouse models
of ischemia upon treatment with TGFα [15]. In this context, seeking
for agents that modulate growth factor release would be a good
strategy to facilitate the generation of new neurons and their
contribution to circuit reformation and function recovery.
ErbB ligands such as amphiregulin or TGFα are released to the
extracellular medium in a proteolytic reaction catalyzed by
convertases of the A Disintegrin and Metalloproteinase (ADAM)
family such as ADAM17 [16]. The selectivity of this enzyme for
each ligand is determined by phosphorylation reactions catalyzed
by kinases of the protein kinase C (PKC) family [17]. PKC consists
on three subfamilies of kinases: the classical, the novel, and the
atypical. Classical PKCα activated by phorbol-12-myristate-13-
acetate (PMA) catalyzes the phosphorylation of TGFα, and
amphiregulin precursors facilitating their shedding mediated by
ADAM17 and releasing the soluble ligand outside the cell.
Similarly, activation of novel PKCδ is required for ADAM17
mediated secretion of neuregulin. Overall, ADAM17 substrate
specificity and selectivity is mediated by the activation of different
PKC isozymes, thus playing a key role in the secretion of different
types of growth factors [17–19].
Received: 27 February 2020 Revised: 24 November 2020 Accepted: 30 November 2020
1Área de Fisiología, Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain; 2Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Cádiz, Spain; 3Área de
Nutrición, Facultad de Medicina Universidad de Cádiz, Cádiz, Spain; 4Departamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain; 5Departamento de
Química Orgánica, Facultad de Ciencias, Universidad de Cádiz, Puerto Real, Spain; 6Departamento de Anatomía y Embriología Humanas, Facultad de Medicina, Universidad de
Cádiz, Cádiz, Spain and 7Present address: Instituto de Investigaciones Marinas (IIM-CSIC), Vigo, Pontevedra, Spain
Correspondence: Carmen Castro (carmen.castro@uca.es)
These authors contributed equally: Samuel Domínguez-García, Ricardo Gómez-Oliva
www.nature.com/npp













Previous reports show that diterpene compounds with
12-deoxyphorbol structure isolated from plants of the Euphorbia
genus, with a capacity to activate specific isozymes of PKC,
promote proliferation of neural progenitors 3 days after direct
intracerebroventricular administration [20]. The purpose of this
work is to study the long-term effect of non-invasive administra-
tion of diterpenes on neurogenesis and cognitive performance,
and understand their mechanism of action.
METHODS
Reagents
Isolation and purification of the 12-deoxyphorbol ER272
(CAS:25090-74-8) was performed in our laboratory as described
previously [20] (see supplementary methods). PKC inhibitors were
purchased from Sigma-Aldrich (St. Louis, MO) and Calbiochem
(Millipore, Billerica, MA). The general inhibitor of PKC bisindolyl-
maleimide I (Gö6850) and the classical PKC inhibitor (Gö6976)
were added to cell cultures at final concentrations of 5 µM and 1
µM, respectively and were added 30min before the addition of
the PKC activators. Other products, unless otherwise indicated,
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Animals
SVZ derived neural progenitor cells (NPC) were isolated from
7-day postnatal CD1 mice and used for in vitro experiments. For
in vivo experiments 2-month-old male CD1 mice were used.
Animals were housed under controlled conditions of temperature
(21–23 °C) and light (LD 12:12) with free access to food
(AO4 standard maintenance diet, SAFE, Épinay-sur-Orge, France)
and water. Care and handling of animals were performed
according to the Guidelines of the European Union Council
(2010/63/EU), and the Spanish regulations (65/2012 and RD53/
2013) for the use of laboratory animals. All studies involving
animals are reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals [21, 22]. The protocols
used have been authorized by the Ethics Committee of the
“Consejería de Agricultura, Pesca y Desarrollo sostenible” of the
Junta de Andalucía”, Spain with the approval numbers 30/03/
2016/038 and 04/03/2020/033.
Intranasal administration of ER272
ER272, was delivered intranasally as previously described [23–25].
Treatments were administered manually while the animal was
placed in a standing position with an extended neck as previously
described [25]. 18 µL of each solution (5 µM ER272 in saline, or
saline as vehicle) was delivered over both nasal cavities alternating
3 µL/each using a micropipette. Mouse was maintained in such
position for 10 additional seconds to ensure all fluid was inhaled.
In all experiments, mice were coded, treatment (vehicle or ER272)
was assigned randomly to code numbers and applied. In addition,
blind quantifications were performed to avoid subjective biases.
ICV administration of ER272
Adult mice were anesthetized and placed on a stereotaxic frame
to administrate ER272 (1 µM), the general PKC inhibitor Gö5068 (1
μM), a combination of ER272 (1 μM) and Gö5068 (1 μM) or vehicle
as previously described [20, 26] (see supplementary methods).
Brain processing and immunohistochemistry
At the end of the treatment brains were perfused with paraformal-
dehyde (PFA) and sliced using a cryotome into 30 µm sections.
Immunohistochemistry was performed as previously described
[20, 26, 27]. See antibodies in Supplementary Tables 1 and 2.
Quantification of neurogenesis in brain sections
Cells positive for BrdU, DCX, GFAP, EGFR, nestin, or Ascl1 in the
SVZ and DG were estimated as described [28, 29]. Positive cells
were counted throughout the entire DG area or lateral and
laterodorsal walls of the lateral ventricles in every fifth section;
14–16 sections per brain where analyzed under fluorescence
microscopy at ×20 magnification. Mice were coded depending on
the treatment and quantification of cells in brain slices was done
in blinded analysis. Cells in the SVZ and DG of both brain
hemispheres have been quantified unless otherwise indicated.
Quantitative analysis of neuronal morphology
Manual quantitative analysis of BrdU+/ß-III-tubulin+ neurons
within the DG of the mouse hippocampus was performed as
described in Henley et al., 2019 [30]. Fluorescence microscopy
images of ß-III-tubulin+/BrdU+ cells were imported into
ImageJ software to quantify cell area and length. Cell and
dendritic area were manually measured using “polygon selec-
tions” tool on ImageJ software, tracing the cell soma and each
neurites. Only projected ß-III-tubulin+ neurites from BrdU+
somas were taken into account. Length of the dendritic arbors of
neurons was manually measured using the “freehand line” tool
on ImageJ software, indicating the start and end of each
dendrite.
SVZ-derived NPC isolation and culture
SVZ- derived cells were isolate following the same procedure
described in Rabaneda et al., 2008 [28]. For in vitro experiments in
proliferation conditions, growth factors EGF and bFGF were used
as indicated in the figure legends (see supplementary methods).
Neurosphere assay
The effect of ER272 was tested by neurosphere assays in order to
evaluate NPC proliferation. ER272 was added at the time of
seeding. All experiments were run by triplicates a minimum of five
independent times. Number and size of neurospheres were
measured as previously described [28, 29] using the software
ImageJ (see supplementary methods).
Neurosphere treatment and transfection
Neurosphere cells were transfected with specific siRNA SmartPool
One target siRNA from Horizon (Cambridge, UK) against each
specific PKC isozyme using Lipofectamine 2000, following the
manufacturer’s instructions as previously described [26]. ER272
was added and cells were maintained for 48 additional hours
before being used for flow cytometry.
Flow cytometry
For proliferation studies, cells were disaggregated from the
neurospheres and fixed in 4% PFA rinsed with PBS and
centrifuged (300 × g; 5 min). Cells were incubated in a blocking
solution (1 mgmL−1 bovine serum albumin and 0.3% Triton X100)
followed by an incubation with fluorescent antibody (Supplemen-
tary Table S1). Cells were then rinsed in PBS, resuspended in FACS
buffer and analyzed in a Attune NxT flow cytometer (Invitrogen).
HEK293T culture, cloning and transfection
HEK293T obtained from ATCC (Manassas, VA, USA) were cultured
and transfected as previously described [31]. After an overnight
incubation, cells were left for 30 min in serum-free Fluorobrite
DMEM (Thermo Fisher Scientific) and used either in time-lapse or
fluorescence experiments (see supplementary methods).
Cloning of human neuregulin and TGFα cDNA fused to GFP and
Cherry
Full-length cDNA encoding the membrane-bound isoform of
human pro-neuregulin-1 β1-type (NRG1, NCBI reference sequence:
NP_039250.2) with mCherry cDNA inserted between nucleotides
93 and 94 of NRG1 open reading frame was cloned into pEGFP-N1
to add EGFP cDNA to the 3′ end. Construct was synthesized by
GeneCust (Boynes, France) to generate the mCherry-NRG1-GFP
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construct. The mCherry-TGFα-GFP construct containing the
human transforming growth factor alpha (TGFA, NCBI reference
sequence: NM_003236.4), containing mCherry cDNA between
nucleotides 126 and 127 of TGFA was built using the same
strategy and synthesized by GeneCust (Boynes, France).
Time lapse experiments and fluorescence analysis of mCherry-
fused TGFα or neuregulin in the culture medium of HEK293T
HEK293T were plated in µ–dishes (35 mm high, Ibidi, Munich,
Germany). Cells were treated with ER272 or inhibitors, and images
were taken as described in figure legends. For fluorescence
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measurements, 200000 HEK293T cells were plated in 1 mL of
medium Costar® 12-well cell culture microplate and fluorescence
in the medium was measured as described in figure legend
(additional information in supplementary methods).
Morris water maze (MWM)
Spatial memory and learning tasks were analyze starting 10 days
before sacrifice using the MWM test in control and treated mice
the 1 day after the NOD test was concluded as previously
described [32] and shown in figure legend (additional information
in supplementary methods).
Motor activity and new object discrimination (NOD) task
Motor activity was analyzed measuring the distance travelled by
each mouse during a 30 s period before initiating the NOD test.
Then integrated episodic memory for the paradigms “what”,
“when” and “where” was analyzed as described in previous reports
[32] (additional information in supplementary methods). In brief,
on the first sample trial, mice were placed into the center of the
box containing three copies of a novel object (yellow balls)
arranged in a triangle-shaped spatial configuration and allowed to
explore them for 5 min. After a delay of 30 min, the mice received
a second sample trial with four novel objects (navy cubes),
arranged in a quadratic-shaped spatial configuration, for 5 min.
After a delay of 30 min, the mice received a test trial with two
copies of the object from sample trial 2 (“recent” objects) placed at
the same position, and two copies of the object from sample trial
1 (“familiar” objects) placed one of them at the same position (“old
non-displaced” object) and the another in a new position (“familiar
displaced” object). Integrated episodic memory for “what”, “where”
and “when” was analyzed as previously described [33–35]: “What”
was defined as the difference in time exploring familiar and recent
objects, “where” was defined as the difference in time exploring
displaced and non-displaced objects and “when” was defined as the
difference between time exploring familiar non displaced and recent
non displaced objects.
Statistical analysis
The data and statistical analysis comply with the recommenda-
tions on experimental design and analysis in pharmacology [36].
Statistical analysis was performed using the computer program
IBM SPSS Statistics 22. Unless otherwise indicated, normal
distribution of the data was first analyzed using a Shapiro–Wilks
test. Then, a Brown Forsythe test was performed to test the
equality of variances. Afterwards, when more than one treatment
group were compared, statistical analyses were performed using
one-way ANOVA followed by a post-hoc Bonferroni’s test unless
otherwise indicated. Two way-ANOVA (group × day) was used in
the acquisition phase of the MWM. A Student’s t test was used
when only one treatment group was compared with the control.
Differences were considered significant at values of p < 0.05. In
general, sample size used in statistical analysis were n= 6–10 for
in vivo experiments and n= 5–9 for in vitro experiments. Sample
sizes were chosen based on previous works related to this one
[26, 29, 31, 37].
RESULTS
Short term intranasal administration of ER272 promotes
proliferation of in the DG and SVZ
Mice given ER272 for 7 days by intranasal administration and
receiving BrdU every 2 days since the first day of treatment
(Fig. 1A), showed a higher number of cells that incorporated BrdU
over the course of the treatment compared to controls, in the SVZ
(Fig. 1B, D) and DG (Fig. 1C, F). In addition, ER272 treatment
increased the number of DCX+ neuroblasts that had incorporated
BrdU in both niches (Fig. 1B, C, E, G). No effect was observed of
ER272 on the number of BrdU+/GFAP+ cells within the SVZ. In the
DG, we observed a reduction in the number of GFAP+ cells that
incorporated BrdU (Supplementary Fig. S1). However, no effect
was observed in the DG regarding the number of mature glial cells
(Supplementary Fig. S2).
The number of Ascl1+ transit amplifying cells in the SVZ
increased in treated mice, whereas no statistically detectable
alterations in the number of Ascl1+ cells or in the percentage of
Ascl1+/BrdU+ of the total BrdU+ cells were observed in the DG
(Supplementary Fig. S3).
Long-term intranasal administration of ER272 promotes
neurogenesis in the DG
The effect of 4 weeks treatment with ER272 on DG neurogenesis
was tested in mice that received BrdU during the first 2 weeks of
treatment (Fig. 2A). As shown in Fig. 2, ER272 increased the
number of BrdU+ cells within the DG (Fig. 2B, C) as well as the
number of mature NeuN+ neurons that had incorporated BrdU
(Fig. 2B, E) (Fig. 2B, D). An elevated number of BrdU/DCX+ cells in
the DG after 28 days of treatment was detected, however the
total number of DCX+ cells remained unaltered (Supplementary
Fig. S4, A-C). Also, we performed a pilot study to analyze whether
ER272 affected the morphology of newly generated neurons. The
morphological analysis of BrdU+/β-III-tubulin+ neurons, recon-
structed as previously described [30], was performed quantifying
the soma area, cell area, maximum neurite length (maximum
distance from soma to a terminal ending/neuron), and the total
neurite length calculated as the summed length of all branches
of a neuron. Quantification was performed according to previous
works [38, 39] in BrdU+ neurons detected as BrdU+/β-III-
tubulin+. Results show no differences in any of these parameters
Fig. 1 Intranasal administration of ER272 promotes neurogenesis in the SVZ and the DG. Intranasal ER272 (1 µM) or only vehicle was
administered during 7 days to healthy 2-month-old adult mice. A Scheme of BrdU administration. All mice were intraperitoneally-injected with
BrdU (100mg/kg) during 7 days every 2 days as described in methods. B Representative confocal microcopy images of the SVZ of adult mice
treated with ER272 or only vehicle. Scale bar= 50 µm. The dotted lines indicate lateral ventricle limits (LV). Slices were processed for the
immunohistochemical detection the proliferation marker BrdU and the neuroblast marker doublecortin (DCX). C Representative confocal
microcopy images of the DG of the hippocampus of adult mice treated with ER272 or only vehicle. Scale bar= 50 µm. The dotted lines
indicate the DG limits. Slides were processed for the immunohistochemical detection the proliferation marker BrdU and the neuroblast marker
doublecortin (DCX). D Graph shows the number of proliferating cells marked with BrdU per mm3 in the SVZ of the indicated animal groups.
Data are the means ± S.E.M of six animals n= 6. Statistical analysis: **p= 0.0033 in two tailed unpaired Student’s t test comparing ER272
treatment with the control group (treated only with vehicle). E Graph shows the number of BrdU+ cells that co-express the neuroblast marker
DCX (doublecortin) in the SVZ per mm3. Data are the means ± S.E.M of six animals n= 6. Statistical analysis: *p= 0.0084 in two tailed unpaired
Student’s t test comparing ER272 treatment with the control group (treated only with vehicle). F Graph shows the number of proliferating cells
marked with BrdU per mm3 in the DG of the hippocampus of the indicated animal groups. Data are the means ± S.E.M of six animals n= 6.
Statistical analysis: ***p= 0.0006 in two tailed unpaired Student’s t test comparing ER272 treatment with the control group (treated only with
vehicle). G Graph shows the number of BrdU+ cells that co-express the neuroblast marker DCX (doublecortin) in the DG of the hippocampus
per mm3. Data are the means ± S.E.M of six animals n= 6. Statistical analysis: *p= 0.0139 in two tailed unpaired Student’s t test comparing
ER272 treatment with the control group (treated only with vehicle).
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in mice treated with ER272 compared to control. Thus, no
alterations on the morphology of newly generated neurons
detected as BrdU+/β-III-tubulin+ were induced by ER272 treat-
ment (Supplementary Fig. S5).
Long-term intranasal administration of ER272 improves
cognitive performance
We next analyzed spatial and episodic memory using the MWM
and NOD tasks. In the MWM control and treated mice
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progressively reduced the time used to find the platform from day
1 to day 4, along the acquisition phase. Although differences
between both groups were found during the training phase on
days 2 and 3, no treatment × day differences were observed
(Fig. 2F) indicating no effect of the treatment on the training
phase. In the retention phase of the MWM, mice treated with
ER272 improved performance. No differences in the time spent in
quadrant 2, where the platform used to be located (quadrant 2)
were detected among groups in the retention phase 24 h after
acquisition, however, ER272 increased the time in quadrant 2, 72 h
after completing the acquisition phase (Fig. 2G). Swimming speed
was not affected by the treatments neither in the 24 h or 72 h
retention phases (Fig. 2H).
Episodic memory was analyzed by the NOD test, finding an
improvement in mice treated with ER272. No differences were
detected for paradigm “what” (p= 0.9333) or “when” (p= 0.319),
however performance for paradigm “where” was significantly
improved after ER272 treatment (p < 0.01 vs. control) (Fig. 2I). No
differences were found in motor activity measured as the distance
moved by these mice (Fig. 2J). These results indicated an
improvement in cognitive performance, particularly in spatial
memory.
ER272 mimics the effect of EGF
To study ER272 mechanism of action, we examined the capacity of
ER272 to mimic the effect of EGFR ligands such as EGF in cultures
using the neurosphere assay. As shown in Fig. 3A, B, the size of the
neurospheres in cultures treated with either EGF or bFGF was
similar, whereas in the presence of both growth factors (EGF+
bFGF), the effect was additive. However, the neurosphere size in
cultures stimulated with ER272 was larger than that of cultures
stimulated with only one of the growth factors, and a combination
of bFGF+ ER272 increased the size of the neurosphere more than
the combination of EGF+ bFGF. On the contrary, the addition of
ER272 to EGF stimulated cultures did not induce an increase in
neurosphere size. These results suggested that ER272 mimicked
the effect of EGF in cultures by either directly activating the
receptor or by inducing the release of EGFR ligands. Similarly,
detection of Ki67 using flow cytometry in cells from neurosphere
cultures revealed that ER272 increased the number of Ki67+ cells,
being more potent than bFGF. The effects of bFGF and ER272
were additive, supporting the hypothesis that ER272 facilitates
EGFR stimulation (Fig. 3C, D). The additive effect of ER272 was not
specific of bGFG. Like EGF, ER272-induced a proliferative effect
even in the presence of another different neurotrophic factor like
BDNF (20 ng/mL) (Supplementary Fig. S6). Neurospheres cultured
only in the presence of BDNF show a smaller size compared to
those cultured in the presence of EGF or ER272. The addition of
both EGF or ER272 to cultures grown with BDNF increased the size
of the neurospheres in a similar manner.
In order to further study the similarities between the effect of
EGFR ligands and ER272 we ruled out the effect of ER272 on
activating two signaling pathways initiated by EGF: the MAPK and
PI3K–AKT pathways. Thus, using the neurosphere assay we
analyzed the effect of ER272 on neurosphere cultures in the
presence of inhibitors of both pathways (10 μM of U0126 and
50 μM of LY94002 respectively). As shown in Fig. 3E, F, the effect of
both EGF and ER272 on neurosphere size was abolished by the
addition of both inhibitors, indicating the role of these two
pathways in the ER272-mediated proliferative effect.
We then investigated whether the administration of ER272
in vivo induced proliferation of EGFR+ cells. Our results show that
a single ICV injection of ER272 in mice that received BrdU during
3 days after the injections, increased the number of BrdU+/EGFR+/
nestin+ undifferentiated progenitors in the SVZ 3 days post
injection (Supplementary Fig. S7), thus supporting the hypothesis
that ER272 facilitated the release of EGFR ligands.
The proliferative effect of ER272 is mediated by classical PKCα
activation
In order to demonstrate that the effect of ER272 on NPC
proliferation in vivo was dependent on PKC activation, we tested
the effect of a single ipsilateral ICV injections of ER272 (1 μM) in
mice in combination with the general PKC Gö6850 (1 μM). As
expected, 3 days after ICV injections of ER272 the total number of
BrdU+ and BrdU+/DCX+ cells in the ipsilateral and contralateral
SVZ and DG increased compared to that of untreated mice,
whereas the PKC inhibitor significantly reduced this number. The
addition of ER272 in combination with the general PKC inhibitor
abolished the proliferative effect in both the SVZ and DG
(Supplementary Fig. S8).
We next examined the PKC subfamily responsible for the
proliferative effect of ER272 using the neurosphere assay. The size
of the neurospheres in cultures treated with ER272 was larger than
Fig. 2 Long term intranasal administration of ER272 promotes neurogenesis in the DG and enhances learning and memory. Intranasal
ER272 (1 µM) or only vehicle was administered during 28 days to healthy 2-month-old adult mice. A Scheme of BrdU administration. All mice
were intraperitoneally-injected with BrdU (100mg/kg) during the first 14 days every 2 days as described in methods. B Representative
confocal microcopy images of the DG of adult mice hippocampus treated with ER272 or only vehicle. Scale bar= 50 µm. The dotted lines
indicate DG limits. Slices were processed for the immunohistochemical detection the proliferation marker BrdU and the neuronal marker
NeuN. C Graph shows the number of proliferating cells marked with BrdU per mm3 in the DG of the indicated animal groups. Data are the
means ± S.E.M of ten animals n= 10. Statistical analysis: *p= 0.0270 in two tailed unpaired Student’s t test comparing ER272 treatment with
the control group (treated only with vehicle). D Graph shows the percentage of NeuN+ cells per mm3 in the DG of the indicated treated
groups. Data are the means ± S.E.M of six animals n= 6. Statistical analysis: *p= 0.034 in two tailed unpaired Student’s t test comparing ER272
treatment with the control group (treated only with vehicle). E Graph shows cells that co-express BrdU and the neuronal marker NeuN per
mm3 in the DG of the hippocampus. Data are the means ± S.E.M of ten animals n= 10. Statistical analysis: *p= 0.040 in two tailed unpaired
Student’s t test comparing ER272 treatment with the control group (treated only with vehicle). F Scape latency in the MWM test during the
4 day acquisition phase. We did not detect a significant treatment × day effect, when we compared the groups under study [F(3, 290)= 1.61
p= 0.186]. Further assessment on individual days revealed that ER272 can significantly reduce the time required to find the platform: day 1
(p= 0.972); day 2 (*p= 0.011 vs. control; statistical power 0.728), day 3 (*p= 0.016 vs. control; statistical power 0.683), day 4 (p= 0.460).
Differences were detected by Student’s t test for independent samples. G Time spent in quadrant 2 during the retention phase 24 and 72 h
after the acquisition test. ER272 treatment improved performance in the retention phase of the MWM. While no differences were detected
among groups in the retention phase, 24 h after acquisition (p= 0.731) in the time spent where the platform used to be located (quadrant 2),
ER272 increased the time in quadrant 2, 72 h after completing the acquisition phase (**p= 0.009 vs. Control). Differences detected by
Student’s t test for independent samples. H Swimming speed was not affected by the treatments in the 24 h (p= 0.539) or 72 h (p= 0.716)
retention phase. Differences detected by Student’s t test for independent samples. I Episodic memory was improved in the new object
discrimination test after ER272 administration. Whereas no differences were detected for parading “what” (p= 0.9333) or “when” (p= 0.319),
performance for paradigm “where” was significantly improved after ER272 treatment (**p < 0.01 vs. Control). Differences were detected by
Student t test for independent samples. J Graph representing motor activity. No differences were detected (p= 0.820) using Student’s t test
for independent samples.
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that of control cultures (Fig. 4A, B). This effect on neurosphere size
was reverted by a classical PKC inhibitor (Fig. 4A, B).
It was next analyzed the effect of ER272 on NPC proliferation
after cells were transfected with siRNAs to block the two classical
PKC isozymes expressed in neurosphere cultures: PKCα PKCβ [26].
Proliferation was tested by analyzing the expression of Ki67 using
flow cytometry (Fig. 4C, D). We observed an increase in the
percentage of Ki67+ cells in cultures treated with ER272 (Fig. 4C, D).
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The effect was not observed in cultures of cells treated with ER272
and transfected with PKCα siRNA. Also, a smaller effect was
observed in cultures of ER272 treated cells transfected with
PKCβ siRNA.
ER272 facilitates TGFα and neuregulin release
In order to demonstrate the effect of ER272 on EGFR ligand
release, we built a construct in which TGFα was expressed in a
fusion protein flanked by GFP in the C-terminal domain and
Cherry in the N-terminal (Fig. 5A). This construct was transfected
into HEK293T cells and by using life imaging we quantified the
variation in the proportion of mCherry/GFP in the cell membrane
upon addition of ER272. Figure 5 shows that addition of vehicle to
mCherry-TGFα-GFP transfected cultures of HEK293 did not induce
any change in the mCherry/GFP ratio (movie 1). However, cells
expressing the TGFα constructs produced a fast change in the
mCherry/GFP ratio (movie 2) after ER272 addition, which was
abolished by the presence of a classical (Gö6976) (Fig. 5B, C) or
general (Gö6850) PKC inhibitor (Fig. 5B, C). To further ensure that
the mCherry-labeled ligand was being released into the culture
medium we analyzed fluorescence in the medium as a ratio to the
green fluorescence in the cell fraction (Fig. 5D). Identical
experiments were performed using a neuregulin 1 construct
(Fig. 5E–G; movies 3, 4). The effect of ER272 on the red/green ratio
when HEK293T cells were transfected with the neuregulin 1
construct was smaller than that found with TGFα and a smaller
reduction of the red/green ratio was observed (Fig. 5E, F). Also, the
amount of fluorescence found in the culture medium was smaller
than that found with the TGFα construct (Fig. 5G).
DISCUSSION
We have found in here that intranasal administration of ER272
promotes proliferation of NPC in both neurogenic niches of the
adult mouse brain. Remarkably, long-term intranasal administra-
tion of this small molecule facilitates differentiation of DG NSC
toward a neuronal phenotype increasing the number of newborn
neurons. Concomitantly, the treatment improves memory and
learning tasks, having a particular impact on spatial memory. The
effect on neurogenesis does not seem to impact cell cycle exit of
quiescence, but it reduces astrogliogenesis. Finally, we have also
elucidated the mechanisms of action of this compound, thus
finding that ER272 stimulates neurogenesis by activating PKCα.
ER272-induced classical PKC activation facilitates TGFα release
and, to a lesser extent, neuregulin 1 release.
Intranasal administration of ER272 promotes neurogenesis in the
adult hippocampus and the SVZ
Previous reports have described the role of the diterpene with 12-
deoxyphorobol structure ER272 in inducing proliferation of neural
progenitors in vitro in cultures of NPC and in mice receiving
single ICV injections of this molecule [20]. The study proposed
this compound as a drug to induce neurogenesis. However, the
study did not demonstrate whether this compound could exert
an effect if administered using a non-invasive methodology or if
longer treatments exerted a neurogenic effect within the niches
improving brain tasks associated with neurogenesis such as
memory and learning performance. We show that intranasal
administration of 12-deoxyphorbol ER272 stimulates proliferation
of progenitors in the SVZ after 7 days of treatment in agreement
with the work of Geribaldi-Doldán et al. [20]. In this particular
region, the number of ASCL+ transit amplifying undifferentiated
progenitors [40, 41] is increased and this may be the reason for
the enlarged number of DCX+ neuroblasts that have incorporated
BrdU indicating a neurogenic role for this compound in the SVZ.
On the contrary, no effect was observed in the generation of
other cells types such as glial cells (GFAP+) in the SVZ. We also
show that ER272 promotes the generation of neuroblasts in the
DG (DCX+/BrdU+ cells) after a 7-day treatment, without affecting
the number of cells that exit quiescence to enter cell cycle (Ascl+
cells) [42], indicating that this compound does not alter the
preservation of the stem cell pool within this region while
exerting its neurogenic effect. This effect was concomitant with a
reduction in the number of GFAP+/BrdU+ cells. However, a long-
term effect on gliogenesis was not observed. A preferential
differentiation of hippocampal NSC into glial cells has been
shown in the DG of mice models of ageing with a reduced
neurogenesis [43, 44]. This suggested a possible effect of ER272 at
preventing the astrogliogenesis that takes place in the aged brain
or under neurodegeneration. However, in the young mice
analyzed in here a long-term effect of the compound on glial
cells has not been found.
Remarkably, we must highlight that a longer ER272 treatment
(4-weeks)-induced neurogenesis in the DG increasing the number
of newly generated neurons in the DG (NeuN+/BrdU+ cells)
indicating that ER272 induces proliferation of cells that differ-
entiate into neurons and survive within the niche for at least
2 weeks. Deficits in adult neurogenesis have been associated with
cognitive impairments, and compromised hippocampal circuitry in
mice models of neurodegenerative disease [45], suggesting again
a possible role for this compound in improving cognitive
performance in individuals with these pathologies.
ER272 improves spatial memory and learning in adult healthy
mice
Accordingly, the stimulation of neurogenesis in the DG was
concomitant with an improvement in spatial memory and learning
tasks of mice treated with ER272 for 28 days. This can be inferred
from the improved performance of treated mice in the MWM test
and in the “where” paradigm of the NOD test. In our hands,
Fig. 3 ER272 mimics the proliferative effect of the epidermal growth factor in vitro. A Representative phase-contrast microscopy images of
neurospheres cultured for 72 h in presence or absence of the indicated growth factors and ER272. Scale bar indicates 100 µm. B Graph shows
the effect of the different treatments on neurospheres area expressed as the percentage of control (only EGF treatment). Data shown are the
mean ± S.E.M. of nine independent measurements. Statistical analysis: ***p < 0.0001 in two tailed unpaired Student’s t test comparing EGF
with EGF+ bFGF and with bFGF+ER272. C Flow cytometry analysis of cells isolated from neurospheres treated under the different conditions
indicated and labelled with anti-Ki67 antibody; left panel: forward/side scatter; central panel: cell count vs. fluorescence intensity in the four
different condition; right panel graph shows the percentage of cells labelled with Ki67 in the four different conditions. D Quantification of
proliferating cells (Ki67+) in flow cytometry plots as those shown in (C). Statistical analysis: *p= 0.0108 in two tailed unpaired Student’s t test
comparing control with bFGF; ***p= 0.0003 comparing control with ER272; **p= 0.0011 comparing control with bFGF+ER272. E
Representative phase-contrast microscopy images of neurospheres treated for 72 h with EGF or ER272 and the MAPK inhibitor U0126 (10 μM)
or the PI3-K inhibitor LY294002 (50 μM). Inhibitors were added 30min before EGF or ER272. Scale bar= 100 μm. F Graph shows the effect of
the different treatments on neurospheres area expressed as the percentage of control (only EGF treatment). Data shown are the mean ± S.E.M.
of nine independent measurements. Statistical analysis: **p= 0.0128 in two tailed unpaired Student’s t test comparing EGF with EGF+U0126.
***p < 0.0001 in two tailed unpaired Student’s t test comparing EGF with EGF and with EGF+ LY294002. **p= 0.0002 in two tailed unpaired
Student’s t test comparing ER272 with ER272+ U0126. ***p < 0.0001 in two tailed unpaired Student’s t test comparing EGF with ER272 and
with ER272+ LY294002.
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ER272 significantly improved “where” paradigm in the NOD test, in
line with observations in the MWM for spatial memory. Whereas
the implication of the hippocampus at this level remains under
study, previous studies have reported the implication of the
hippocampus for the object recognition memory [46] and that
hippocampus is crucial for object location, object-in place and
recency recognition memory [47]. The discrimination of simple
geometric shapes, as those used in our NOD test, have been
described to be hippocampal dependent [47]. The improvement
of ER272 treated mice was similar to that found in healthy mice
treated with insulin by intranasal administration [48]. This suggests
that the effect of ER272 on memory tasks may be as potent as
other neurogenic drugs such as insulin [48, 49]. However, we have
not been able to directly demonstrate that the induction of
neurogenesis is responsible for the improvement in memory and
learning tasks. Notwithstanding, it has thoroughly been demon-
strated that newborn neurons at different maturation stages may
contribute to hippocampal circuits by either rewiring pre-existing
circuits [50], or establishing new memory codes that determine
pattern separation [51–53]. Therefore, it is likely that the enhanced
neurogenesis found in mice treated with ER272 is responsible for
the improvement in memory and learning tasks.
ER272 mechanisms of action
ER272 effect on proliferation in vitro and in vivo is dependent on
PKC activity in vitro [20]. However, the mechanism of action of
ER272 needed to be elucidated. In here, we have determined that
classical PKCα isozyme is responsible for the proliferative effect of
ER272 in vitro. The role of PKCβ in the effect, was not as significant
as that of PKCα. A similar diterpene with lathyrane structure, ELAC,
with the capacity to induce proliferation of SVZ transit amplifying
progenitors has previously been associated to the activation of
classical PKCβ [26]. In light of these results it is likely that 12-
deoxyphorbols have a higher affinity for the regulatory domain of
PKCα whereas lathyrane molecules have a higher affinity for the
regulatory domain of PKCβ.
Fig. 4 ER272 induces proliferation via classical PKC activation in NPC cultures. A Representative phase-contrast microscopy images of
neurospheres cultured for 72 h in presence or absence of the basic fibroblastic growth factor (bFGF), ER272 or the classical PKC inhibitor
(Gö6976). Scale bar indicates 100 µm. B Graph shows the effect of the different treatments on neurospheres area expressed as the percentage
of control (bFGF treatment). Data shown are the mean ± S.E.M. of nine independent measurements. Statistical analysis: *p= 0.037 in two tailed
unpaired Student’s t test comparing bFGF with bFGF+ER272. C Flow cytometry analysis of cells isolated from neurospheres treated under the
different conditions indicated and labelled with anti- Ki67 antibody; left panel: forward/side scatter; right panel: cell count vs. fluorescence
intensity in the six different conditions indicated. D Quantification of proliferating cells (Ki67+) in flow cytometry plots as those shown in (C).
Statistical analysis: one-way ANOVA test: ***p= 0.0005, bFGF+ ER272 vs. bFGF; ***p= 0.0004 bFGF+ ER272 vs. bFGF+ siRNA α; ***p < 0.0001
bFGF+ ER272 vs. bFGF+ ER272+ siRNA α; *p= 0.0165, bFGF+ ER272 vs. bFGF+ ER272+ siRNA β.
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Our results demonstrate the involvement of PKC in the
neurogenic effect of ER272 in neurogenic niches in vivo since
the PKC inhibitor abolished the neurogenic effect of ER272 in both
the SVZ and DG. In addition, our in vitro findings also assign a role
for PKCα in neurogenesis in both niches participating in the
release of TGFα and less significantly neuregulin. The effect of
ER272 on TGFα release in vivo, is supported by the fact that ICV
injections of ER272 promote proliferation of EGFR+ undifferen-
tiated progenitors in the SVZ.
Classical and novel PKC isozymes can be activated by
nonphysiological molecules such as phorbol esters. These tetra-
cyclic diterpenoids activate PKC because they mimic the action of
diacylglycerol [54]. Recent reports demonstrate that activation of
specific PKC isozymes determines ADAM17 selectivity for its
different substrates. Thus, TGFα phosphorylation by classical PKCα
activated by PMA facilitates its shedding mediated by ADAM17
[17, 18]. On the contrary, activation of novel PKCδ is required for
ADAM17 mediated secretion of neuregulin. Phosphorylation of
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serine 286 in the cytoplasmic domain of neuregulin catalyzed by
PKCδ facilitates the scission of its ectodomain [17, 18] releasing
neuregulin into the extracellular medium. Overall, this indicates
that ADAM17 substrate specificity and selectivity is mediated by
the activation of different PKC isozymes, thus playing a key role in
the secretion of different types of ligands [17, 18]. We show that
treatment with ER272 of HEK293T cells transfected with a TGFα
flanked by mCherry and GFP induces the release of TGFα
quantified as the ratio of mCherry fluorescence released outside
the cells. In addition, a smaller release of neuregulin 1 has also
been observed in cells transfected with a similar construct in
which neuregulin 1 is fused to mCherry and GFP in a similar way.
These results indicate that ER272 exerts a more potent effect at
releasing TGFα than other ligands such as neuregulin. It is likely
that ER272 has a higher affinity for the regulatory site of classical
PKC isozymes, responsible for the release of TGFα, than for that of
novel isozymes, responsible for the release of neuregulin.
An effect of neuregulin in DG neurogenesis and behavior has
previously been reported by Mahar et al. who find that
neuregulin 1 administration increases ErbB3 phosphorylation
in the DG, together with a neurogenic effect of neuregulin 1 on
the generation of newborn neurons [14]. Neuregulin 1 and
ErbB3 downregulation in granule cells neurons within the
hippocampus has been reported in suicidal subjects, an effect
that is reverted with antidepressants suggesting a role for
neuregulin 1 and antidepressants in the prevention of this
particular behavior [13]. Therefore, treatment with ER272 might
induce the release of neuregulin 1, thus acting as a putative
compound in the development of antidepressant drugs. Also,
neuregulin mutations have been involved in cognitive impair-
ment in schizophrenic [55] and other neuregulins such as
neuregulin 2 have been shown to contribute to the maturation
of granule cell neurons, thus indicating a role for neuregulins in
the regulation of cognitive tasks. An effect of TGFα on
hippocampal neurogenesis and memory performance has also
been described in the hippocampus in models of ischemia [15].
TGFα expression increases as a response to injuries, however, a
physiological role for TGFα on hippocampal neurogenesis, still
remains to be investigated. In here, we show that ER272 in vitro
mimics the effect of EGFR ligands mediating its effect through
pathways initiated by ligands such as TGFα (MAPK and PI3K-AKT
signaling pathways) thus supporting the hypothesis of its role in
TGFα release. Interestingly, experimental models in which these
pathways are inhibited as a consequence of metabolic altera-
tions such as mice models of hyperhomocysteinemia or the
mice model of hypermethioninemia Gnmt−/− mice show a
deficient neurogenesis in both the DG and the SVZ [28, 29, 37]
and a concomitant cognitive impairment [37].
In conclusion, we have found that intranasal treatment of mice
with ER272 promotes neurogenesis and improves cognitive
performance. This compound facilitates the release of growth
factors that activate ErbB receptors such as neuregulin or TGFα,
suggesting a role for ER272 as a possible drug to promote
neurogenesis in diseases associated with cognitive impairment.
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